RecruitingPhase 1Phase 2NCT06239324

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment


Sponsor

Egymedicalpedia

Enrollment

70 participants

Start Date

Feb 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse of the immune privilege of the hair follicle caused by immunological mechanism. Multiple genetic, environment factors and psychological stress contribute to the pathogenesis of Alopecia Areata . Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as Janus kinase inhibitors, biologics and several small molecular agents. In addition, modern therapies for AA, including antihistamines, platelet-rich plasma injection


Eligibility

Min Age: 30 YearsMax Age: 35 Years

Inclusion Criteria1

  • Patients of both sexes with localized stable alopecia areata of the scalp of 3 months duration at least.

Exclusion Criteria5

  • Acute or chronic infections.
  • Pregnant or lactating women.
  • Scarring alopecia.
  • Alopecia totalis , Alopecia universalis and ophiasis.
  • Autoimmune dermatological diseases.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLatanoprost

Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.


Locations(1)

Qena Hospital

Qina, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06239324


Related Trials